Drugs / A82
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06360250 | Apr → Oct 2024 | tetanus | Changchun BCHT Biotechnology Co. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A82 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06360250 ↗ |
| Modality | Monoclonal antibody | “fully human anti-tetanus toxin monoclonal antibody A82” NCT06360250 ↗ |